Expression of miR‑296‑5p as predictive marker for radiotherapy resistance in early‑stage laryngeal carcinoma
Carregando...
Data
2015-08
Título da Revista
ISSN da Revista
Título de Volume
Editor
Resumo
Purpose: Definitive radiation therapy is the mainstay of treatment for early stage laryngeal squamous cell carcinoma
(LSCC). However, up to 30% of the patients do not respond to radiotherapy. Unfortunately, we are unable to predict
which tumors are likely to respond to radiation, and which will be resistant and persist. Therefore, the development
of novel markers to predict response to radiotherapy is urgently needed. This study was designed to evaluate the
expression pattern of microRNAs (miRNAs) in LSCC in order to identify markers capable of segregating radioresistant
and radiosensitive tumors and to investigate the relationship between the expression of these miRNAs and the
prognosis of LSCC.
Methods: The expression profile of 667 miRNAs was determined in an initial screening of nine early-stage LSCC samples
(5 radioresistant and 4 radiosensitive) using TaqMan Low-Density Array (TLDA). Real-time polymerase chain reactions
were performed to validate the expression of selected miRNAs in an expanded LSCC cohort (20 radioresistant
and 14 radiosensitive). The miRNA expression level was scored as high or low based on the median of the expression
in the LSCC samples.
Results: A comprehensive miRNA expression profiling enabled the identification of four miRNAs (miR-296-5p miR-
452, miR-183* and miR-200c) differentially expressed in radioresistant LSCC. Moreover, the analysis of additional 34
LSCC samples, confirmed the expression of miR-296-5p as significantly related to radioresistance (p = 0.002) as well as
an association of this marker with recurrence (p = 0.025) in early stage laryngeal cancer.
Conclusions: This study indicates that miR-296-5p expression is associated with resistance to radiotherapy and
tumor recurrence in early stage LSCC, showing the feasibility of this marker as a novel prognostic factor for this malignance.
Furthermore, miR-296-5p expression could be helpful in the identification of tumors resistant to radiotherapy;
thus aiding the clinicians in the choice of the best therapeutic scheme to be used in each case.
Descrição
Palavras-chave
Early-stage laryngeal cancers, miR-296-5p, Molecular marker, MicroRNAs, Radioresistance
Citação
MAIA, Danielle et al. Expression of miR-296-5p as predictive marker for radiotherapy resistance in early-stage laryngeal carcinoma. Journal of Translational Medicine, London, v. 13, p. 262-273, Aug. 2015.